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Abstract 
Background: There is controversy whether patients diagnosed with large-cell neuroendocrine carcinoma (LCNEC) 
should be treated according to protocols for non-small cell lung cancers (NSCLC) or small cell lung cancers (SCLC), 
especially with regard to the administration of prophylactic cranial irradiation (PCI). This study was set up to determine 
the incidence of brain metastases and to investigate the outcome following multimodal treatment in 70 patients with 
LCNEC.
Methods: Seventy patients with histologically confirmed LCNEC were treated at the University Hospital of Heidel-
berg between 2001 and 2014. Data were collected retrospectively. Al most all patients received thoracic surgery as ini-
tial treatment (94 %). Chemotherapy was administered in 32 patients as part of the initial treatment. Fourteen patients 
were treated with adjuvant or definitive thoracic radiotherapy according to NSCLC protocols. Cranial radiotherapy due 
to brain metastases, mostly given as whole brain radiotherapy (WBRT), was received by fourteen patients. Statistical 
analysis was performed using the long-rank test and the Kaplan–Meier method.
Results: Without PCI, the detected rate for brain metastases was 25 % after a median follow-up time of 23.4 months, 
which is comparable to NSCLC patients in general. Overall (OS), local (LPFS), brain metastases-free survival (BMFS) and 
extracranial distant progression-free survival (eDPFS) was 43, 50, 63 and 50 % at 5 years, respectively. Patients with 
incomplete resection showed a survival benefit from adjuvant radiotherapy. The administration of adjuvant chemo-
therapy improved the general worse prognosis in higher pathologic stages.
Conclusion: In LCNEC patients, the administration of radiotherapy according to NSCLC guidelines appears reason-
able and contributes to acceptable results of multimodal treatment regimes. The low incidence of spontaneous brain 
metastases questions a possible role of PCI.
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Background
The incidence of large-cell neuroendocrine carcinoma 
(LCNEC) is low as it accounts for about 3 % of all lung 
cancer cases [1, 2]. Patients diagnosed with LCNEC 
suffer from a very dismal prognosis with 5-year overall 
survival rates between 15 and 57 % [2–5]. During the last 
years, several reports suggested similarities in histology, 
clinical behavior and biology of LCNEC and small cell 
lung cancer (SCLC) [6–9]. Histological differentiation 
between LCNEC and SCLC can be challenging as both 
tumor entities often share many common features: neu-
roendocrine morphology, high mitotic rate, large zones 
of necrosis and positive immunohistochemical staining 
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for neuroendocrine markers [10, 11]. Furthermore, both 
LCNEC and SCLC are characterized by common clinical 
aspects including a predominance of males and smokers 
and aggressive clinical courses [11–13]. In addition, Jones 
et  al. found comparable genetic alterations in LCNEC 
and SCLC and were unable to distinguish LCNEC from 
SCLC by gene expression profiling [14]. However, Ull-
mann et al. and Hiroshima et al. showed that LCNEC and 
SCLC harbor distinct morphological, phenotypical and 
genetical differences [15, 16]. Moreover, analyzing 1,211 
patients with LCNEC from the Surveillance, Epidemiol-
ogy, and End Results (SEER) program of the US National 
Cancer Institute, Varlotto et  al. reported that the clini-
cal, histopathological and biological characteristics of 
LCNEC were more similar to large-cell carcinoma than 
to SCLC [17]. Additionally, the World Health Organiza-
tion still categorizes LCNEC in the group of NSCLC.
Due to the complex clinical, histopathological and 
biological characteristics of LCNEC, it remains uncer-
tain whether patients diagnosed with LCNEC should 
be treated according to NSCLC-based or SCLC-based 
regimes [11, 13, 17]. Current treatment strategies for 
patients with LCNEC are a mixture between guidelines 
for NSCLC and SCLC patients: while surgical resection 
is recommended for all non-metastatic stages analog to 
NSCLC treatment guidelines, adjuvant chemotherapy 
(when needed) is administered according to SCLC pro-
tocols [13, 18].
In general, treatment strategies also differ strongly 
between SCLC and NSCLC regarding radiotherapy. 
Patients diagnosed with SCLC with cN0 and pN1 nodal 
involvement (limited stage) are treated with thoracic 
radiotherapy, while patients with NSCLC only benefit 
from adjuvant radiotherapy in N2 nodal stages [19–21]. 
Prophylactic cranial irradiation (PCI) is recommended 
in patients with SCLC, as it prolongs both disease-free 
and overall survival [22, 23]. On the contrary, PCI is not 
administered in patients with NSCLC, as Gore et al. only 
showed a decreased rate of brain metastases after PCI 
and were not able to detect any significant improvement 
of overall and disease-free survival after PCI in stage III 
lung cancer [24]. As treatment strategies vary strongly 
between SCLC and NSCLC, it is of major interest to 
find out more about the appropriate treatment regarding 
radiotherapy for patients with LCNEC.
Methods
Between 2001 and 2014, seventy patients with histologi-
cally confirmed large-cell neuroendocrine carcinoma of 
the lung were treated at the University Hospital in Hei-
delberg, Germany. This retrospective analysis was per-
formed with ethical approval by the ethic committee of 
the University Hospital Heidelberg. Median follow-up 
time was 23 months (range 0–155 months). One patient 
was lost to follow-up after 18 months. Detailed patients’ 
characteristics are shown in Table 1. For tumor grading 
and staging, the 7th lung cancer TNM classification was 
used [25, 26]. In our cohort, most patients suffered from 
locally advanced stages (IIA–IIIB), while stage IV was 
only detected in seven patients.
Almost all patients underwent thoracic surgery as 
part of the initial treatment (93 %) (Table 1). According 
to current discussions and treatment recommendations, 
even some patients in oligometastatic tumor stage IV 
who were in good general health conditions and only suf-
fered from few comorbidities received thoracic surgery 
Table 1 Characteristics of  70 patients diagnosed 
with large-cell neuroendocrine carcinoma of the lung
Factor LCNEC (n = 70)
Sex
 Male 52 (72 %)
 Female 18 (28 %)
Median age (range) 63 years (41–81)
 Over 70 years 20 (29 %)
 Under 70 years or 70 years 50 (71 %)
TNM stage (7th classification)
 IA/IB 9/10
 IIA/IIB 15/9
 IIIA/IIIB 18/2
 IVA/IVB 7
Thoracic surgery 66 (94 %)
 Primary 65 (93 %)
  Wedge resection 4 (6 %)
  Lobectomy 53 (81 %)
  Bilobectomy 3 (5 %)
  Pneumonectomy 5 (8 %)
Chemotherapy 36 (51 %)
 Definitive 4 (6 %)
 Adjuvant 32 (46 %)
 Relapse/progress 14 (20 %)
Thoracic radiotherapy 17 (24 %)
 Definitive 4 (6 %)
 Adjuvant/additive 10 (14 %)
 Relapse/progress 3 (4 %)
First line therapy brain metastases 17 (24 %)
 Resection 7 (10 %)
 Stereotactic irradiation 2 (3 %)
 Whole brain irradiation 6 (9 %)
 Best supportive care 2 (3 %)
Prophylactic cranial irradiation (PCI) 3 (4 %)
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[27, 28]. The discussion upon treatment in any case was 
taken by an interdisciplinary tumorboard conference.
Depending on comorbidity, age and cardiopulmo-
nal function, chemotherapy was mostly administered 
postoperatively in stage IIA–IIIA according to the Ger-
man S3-guideline [29]. The types of chemotherapeutic 
regimes were decided by the treating interdisciplinary 
team according to the current German S3-guideline at 
that time (Table 2).
Thirty-two patients received adjuvant chemotherapy 
after thoracic surgery. Of these patients, sixteen patients 
were treated according to SCLC-based regimes, while 
the further sixteen patients received chemotherapeutic 
treatment according to NSCLC-based regimes (Table 2). 
Stage IV patients without surgical resection were sub-
jected to primary palliative (radio-) chemotherapy. Upon 
metastatic recurrence, seven patients received palliative 
chemotherapy.
Postoperative thoracic radiotherapy was adminis-
tered in N2 stages and incomplete resections (R1 or R2). 
Doses with 50–60  Gy were used. Patients diagnosed 
with tumors at higher stages without surgical treatment 
options were treated with simultaneous radiochemother-
apy administering photon doses of 66.0–70.5 Gy.
Two patients already suffered from brain metastases 
at the date of initial diagnosis, while seventeen patients 
developed brain metastases during follow-up time. All 
patients either received contrast-enhanced CT or MRI 
scan of the brain at initial diagnosis for staging. Before 
2010, only CT scans were performed, afterwards 48 % of 
the patients were subjected to cranial staging with MRI. 
Treatment for brain metastases comprised whole brain 
radiotherapy, stereotactic irradiation and surgery. Three 
patients with locally advanced tumors received (PCI) 
with a total dose of 30.0 Gy, single dose 2.0 Gy at initial 
diagnosis of LCNEC. Two of these patients received MRI 
scans, while one patient was staged using cranial CT due 
to claustrophobia.
Statistical analysis
Overall survival (OS) was calculated in months from the 
date of initial diagnosis until the last date of follow-up 
or death. Progression-free survival (PFS), local progres-
sion-free survival (LPFS), brain metastases-free survival 
(BMFS) and extracranial distant progression-free sur-
vival (DPFS), as well as brain metastases-free survival, 
were calculated from the date of primary diagnosis until 
the first imaging diagnosis of recurrent disease. Death 
due to any cause or lost to follow-up (one patient) was 
taken as an event. Data analysis was censored as not all 
patients suffered from an event during follow-up time. 
The Kaplan–Meier method was used to display results. 
Survival curves were compared between groups in a 
univariate analysis using the long-rank test. All statisti-
cal analyses were performed with a software tool (SPSS 
20.0).
Results
The follow-up period for the patients in this study ranged 
from 0  months to 155  months. The median follow-up 
time was 23 months. The survival curve for the seventy 
patients with LCNEC is shown in Fig. 1a. The 2-year and 
the 5-year overall survival rates (OS) were 74 and 43 %, 
respectively. Survival was dependent on tumor stage: 
patients with stage I–II LCNEC showed 2- and 5-year 
overall survival rates of 67 and 48 %, while patients diag-
nosed with stage III–IV LCNEC had a 2- and 5-year 
overall survival of 39 and 29  %. 2- and 5-year progres-
sion-free survival rates (PFS) were 74 and 38 %, respec-
tively (Fig. 1b). Local progression-free survival was 75 % 
after 2 years and 50 % after 5 years (Fig. 1c). 2- and 5-year 
extracranial distant progression-free survival was 53 and 
50 %, respectively (Fig. 1d).
Brain metastases
Seventeen patients (25  %) were diagnosed with brain 
metastases during follow-up. While 9 patients only suf-
fered from 1 to 2 brain metastases, 8 patients presented 
with disseminated metastases (more than three). Patients 
presenting with 1–2 metastases either received surgical 
resection or radiosurgery. Hence, brain metastases-free 
survival was 85  % after 2  years and 63  % after 5  years 
(Fig.  2a). Brain metastases-free survival was not influ-
enced by age and sex. Interestingly, the development of 
brain metastases was significantly associated with patho-
logic stage when comparing stage I vs. stage II–IV tumors 
(p = 0.045; Fig. 2b).
Patients with brain metastases suffered from signifi-
cantly reduced overall survival with 2- and 5-year rates 
Table 2 Different adjuvant chemotherapeutic regimes 
used in treatment of patients with LCNEC
Chemotherapeutic regime N
SCLC-based regimes
 Cisplatin/etoposide 11
 Carboplatin/etoposide 5
NSCLC-based regimes
 Carboplatin/paclitaxel 3
 Carboplatin/gemcitabine 1
 Carboplatin/vinorelbine 3
 Cisplatin/permetrexed 1
 Cisplatin/vinorelbine 5
 Cisplatin/doxetaxel 2
 Gemcitabine 1
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of 37 and 16 %, while patients without brain metastases 
showed 2- and 5-year overall survival rates of 69 and 
54  %, respectively (p  =  0.002). Along with the intro-
duction of SCLC-derived chemotherapy regimes, three 
patients with advanced tumor stages received prophy-
lactic cranial irradiation (PCI). Patients with PCI did 
not develop brain metastases during follow-up time 
(8.2 months). During follow-up time, 37 (53 %) LCNEC 
patients developed progression with local relapse in 25 
patients (36  %) and distant progression in 28 patients 
(40  %). First relapse was distant in 6 (16  %) and com-
bined local and distant at the same time in 31 patients 
(83.4 %).
Apart from the patients with cerebral metastases, 17 
patients (24  %) developed distant metastases: liver (7), 
bone (7), adrenal (4) and lung (2).
Fig. 1 Overall (a) and progression-free (b), local (c) and extracranial distant progression-free survival (d) in 70 patients with LCNEC.
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Treatment concepts
Patients with incompletely resected LCNEC tumors 
received postoperative radiotherapy and showed non-
inferior survival rates with 2- and 5-year overall survival 
of 50 and 30  %, respectively (p =  0.89). In addition, we 
analyzed the different treatment concepts regarding over-
all and disease-free survival. Chemotherapy was adminis-
tered in heterogeneous regimes (Table  2). According to 
the German S3-guideline, patients in higher stages were 
treated with adjuvant chemo-, radio- or radiochemother-
apy after primary resection [29]. Regarding overall sur-
vival, we compared patients who only received resection 
as primary treatment (n = 34; 53 %) to the patients who 
were treated with resection and adjuvant chemo-, radio- 
or radiochemotherapy, mainly because of higher tumor 
stages (≥IIIA) (n = 30; 47 %). Both groups did not differ 
in overall survival (p = 0.298) (Fig. 3). Additionally, local 
progression-free survival was also not significantly differ-
ent between these two groups (p = 0.412). Furthermore, 
comparing chemotherapy regimes derived from SCLC vs. 
NSCLC protocols, we did not detect a difference in treat-
ment results and patient outcome.
Discussion
In the present study, we evaluated incidence of brain 
metastases, treatment outcome and prognostic factors 
in 70 patients with LCNEC who received multimodal 
treatment. In our cohort, 17 patients (25  %) were diag-
nosed with brain metastases during follow-up of 2 years. 
In NSCLC, 20–30 % of patients are diagnosed with brain 
metastases, while in SCLC already 50 % of patients suf-
fer from brain metastases 2  years after initial diagnosis 
[22, 30, 31]. Due to the complex clinicopathological and 
biological features of patients with LCNEC, there is no 
Fig. 2 Brain metastases-free survival (a) is significantly dependent on tumor stages (b) (p = 0.045).
Fig. 3 Adjuvant chemotherapy in higher pathologic stages improves 
overall survival.
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consensus on whether LCNEC should be treated accord-
ing to SCLC or NSCLC protocols [13]. Among others, 
Sun et al. claimed that LCNEC should receive treatment 
similar to SCLC, while Varlotto et  al. insisted on treat-
ing LCNEC with NSCLC treatment regimes [11, 17, 32]. 
As Aupérin et  al. showed that prophylactic cranial irra-
diation (PCI) improves both overall and disease-free 
survival among patients with limited disease SCLC in 
complete remission, PCI became standard treatment in 
patients with limited disease SCLC [22, 29]. Some years 
later, Slotman et  al. established PCI for patients with 
extensive disease SCLC [23]. Regarding patients diag-
nosed with NSCLC, prophylactic cranial irradiation is 
usually not recommended in higher pathologic stages. 
Gore et al. only detected a decreased rate of brain metas-
tases after PCI and were not able to show any significant 
improvement of overall or disease-free survival after PCI 
in stage III lung cancer [24, 29]. Nevertheless, Iyoda et al. 
proposed that PCI might be promising for patients with 
LCNEC [33]. Indeed, the three patients who received 
PCI in our cohort did not develop brain metastases dur-
ing follow-up time (8.23 months). However, in our study 
25 % of patients developed brain metastases during fol-
low-up which is comparable to patients with NSCLC and 
not to patients with SCLC. Similar to our results, Iyoda 
et  al. showed that about 19  % of the analyzed LCNEC 
patients developed brain metastases [32, 34]. Interest-
ingly, the development of brain metastases was sig-
nificantly associated with pathologic TNM stage in our 
cohort. We detected a continuous, non-saturable but 
shallow decline in brain metastases-free survival. In gen-
eral, patients with SCLC in lower stages tend to show the 
greatest benefit from PCI [22]. As on the one hand, only 
few LCNEC patients develop brain metastases and on 
the other hand, there was a strong correlation between 
pathologic stage and the development of brain metasta-
ses in our study, prophylactic cranial irradiation (PCI) in 
patients with LCNEC should be reconsidered thoroughly, 
especially in lower tumors stages.
LCNEC used to be only treated by resection in all 
tumor stages and therefore showed poor survival rates 
[1, 35, 36]. Adjuvant therapy, mainly chemotherapy, led 
to a subsequent improvement in survival in patients 
with higher tumor stages [5, 37, 38]. In NSCLC, adju-
vant thoracic radiotherapy is only recommended in pN2 
and higher nodal stages and after incomplete resection. 
On the contrary, patients with SCLC benefit from tho-
racic radiotherapy when diagnosed with cN0 and pN1 
nodal involvement (limited stage) [19–21, 29]. LCNEC 
tumors appear to be radiation responsive as patients with 
incompletely resected LCNEC and adjuvant radiotherapy 
showed non-inferior survival. However, excellent local 
control was detected in patients with limited thoracic 
tumor extension. Hence, radiotherapy is not needed in 
lower tumor stages and should only be applied according 
to NSCLC treatment protocols.
Sarkaria et  al. reported that LCNEC had a high 
response rate to platinum-based chemotherapy. Further-
more, resected advanced stage patients receiving com-
bination neoadjuvant and (or) adjuvant chemotherapy 
tended to have a survival benefit [39]. Correspondently, 
additional treatment with adjuvant or additive chemo-, 
radio-, or radiochemotherapy in higher stage large-cell 
neuroendocrine carcinoma led to overall survival rates 
comparable to patients who underwent surgery only 
for low-stage NSCLC. This fact underlines the impor-
tance of adjuvant treatment in LCNEC regarding over-
all survival. Sun et  al. revealed that the response rate 
to platinum-based chemotherapy was 60  % in LCNEC 
patients, whereas the response rate of non-platinum-
based chemotherapy was only 11  % [11]. Interestingly, 
all but one patient in our cohort received adjuvant plat-
inum-based chemotherapy which might have led to the 
improved survival rates. Yamazaki et  al. also reported a 
similar response rate to platinum-based chemotherapy 
and suggested that the response rate of LCNEC patients 
was comparable to that of SCLC patients [40]. Due to 
the good response rate to platinum-based chemotherapy 
and the partly comparable histopathological features of 
LCNEC and SCLC, mainly chemotherapeutic regimes 
used in the treatment of SCLC were evaluated within the 
last years [10].
In our cohort, treatment results and patient outcome 
was not significantly different comparing chemotherapy 
regimes derived from SCLC versus NSCLC patients. 
This may be related to platinum administration in both 
SCLC and NSCLC regimes in our cohort (Table 2). Rossi 
et al. analyzed 83 patients with LCNEC and showed that 
SCLC-based chemotherapy (platinum-etoposide) was an 
important variable significantly correlating with survival, 
both in adjuvant and metastatic settings [41]. Iyoda et al. 
started a prospective trial of adjuvant chemotherapy with 
platinum and etoposide and reported that SCLC-based 
chemotherapy appeared promising for the improvement 
of overall survival in LCNEC patients [42]. Similarly, 
Treut et  al. conducted a multicenter phase II study and 
found that the outcomes of advanced LCNEC treated 
with cisplatin and etoposide were comparable to that of 
advanced SCLC [43]. Recently, a phase III trial compar-
ing irinotecan and cisplatin with etoposide and cispl-
atin in adjuvant chemotherapy for completely resected 
LCNEC was initiated [44].
Conclusion
Despite poor survival rates, only 25 % of LCNEC patients 
developed brain metastases and therefore, PCI should 
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not be considered a standard component of LCNEC 
treatment regimes. Adjuvant or additive therapy accord-
ing to the current German S3-guideline in higher stage 
large-cell neuroendocrine carcinoma led to overall sur-
vival rates comparable to patients who underwent sur-
gery only for low-stage NSCLC, putting emphasis on 
the need for most effective first-line treatments. Despite 
its rare occurrence, prospective multi-center trials are 
needed to truly evaluate the optimal multi-modal therapy 
for patients with LCNEC.
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